Bibliografias temáticas / Sepia International Inc

Literatura científica selecionada sobre o tema "Sepia International Inc"

Autor: Grafiati
Publicado: 26 de julho de 2024

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Índice

Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Sepia International Inc".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Artigos de revistas sobre o assunto "Sepia International Inc"

1

Singh, Bhim, e Vashist Bist. "Power-Quality Improvement in PFC Bridgeless SEPIC-Fed BLDC Motor Drive". International Journal of Emerging Electric Power Systems 14, n.º 3 (21 de junho de 2013): 285–96. http://dx.doi.org/10.1515/ijeeps-2012-0014.

Texto completo da fonte
Resumo:
Abstract This article presents a design of a power factor correction (PFC)-based brushless DC (BLDC) motor drive. The speed control of BLDC motor is achieved by controlling the DC link voltage of the voltage source inverter (VSI) feeding BLDC motor using a single voltage sensor. A front-end bridgeless single-ended primary inductance converter (SEPIC) is used for DC link voltage control and PFC operation. A bridgeless SEPIC is designed to operate in discontinuous inductor current mode (DICM) thus utilizing a simple control scheme of voltage follower. An electronic commutation of BLDC motor is used for VSI to operate in a low-frequency operation for reduced switching losses in the VSI. Moreover, a bridgeless topology offers less conduction losses due to absence of diode bridge rectifier for further increasing the efficiency. The proposed BLDC motor drive is designed to operate over a wide range of speed control with an improved power-quality at the AC mains under the recommended international power-quality standards such as IEC 61000–3-2.
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Behdad, Amir, Charles Warren Ross, Joshua Jacques, Usha Kota, Noah A. Brown, David Keren e Lloyd Stoolman. "Utility Of 9-Color, 11-Parameter Flow Cytometry For Detection Of Plasma Cell Neoplasms: A Comparison With Bone Marrow Morphologic Findings and Concurrent M-Protein Studies In Serum and Urine". Blood 122, n.º 21 (15 de novembro de 2013): 3129. http://dx.doi.org/10.1182/blood.v122.21.3129.3129.

Texto completo da fonte
Resumo:
Abstract Background Multiparameter flow cytometry (MFC) is a widely available laboratory platform used for primary diagnosis of mature B-cell and plasma cell (PC) neoplasms. Ongoing advances in myeloma therapeutics have drawn attention to the need for advanced laboratory methods for monitoring disease response and defining disease eradication. Recent literature indicates that achievement of remission based on sensitive MFC criteria is prognostically superior to remissions defined by older criteria based on monitoring of paraproteins in blood and urine. As such, the International Myeloma Working Group (IMWG) recommends MFC for minimal residual disease (MRD) testing during clinical trials for multiple myeloma (MM). This study validates a sensitive 9-color, 11-parameter, two-tube MFC assay suitable for both the initial diagnosis of patients with paraproteinemias and MRD monitoring in MM. Method We established and validated a 9-color, 11-parameter MFC assay in our laboratory. The 9-color tube contained cytoplasmic κ/cytoplasmic λ/CD45/CD38/CD56/CD138/CD19/CD117/CD20. Results of the MFC were compared to bone marrow microscopic examinations, immunohistochemical (IHC) studies and serum/urine M-protein measurements ordered on 363 samples from patients with documented or suspected PC neoplasms and IgM paraproteinemias. Results Total preparation time is approximately 90 minutes (“hands-on” time under 30 minutes) for up to 3 concurrent specimens. The assay is performed in two tubes (control and PC panel) with analysis of up to 1.8 x 106 total bone marrow cells/tube. The mean instrument analysis time was ∼5 minutes/tube (range 1-9 minutes). MFC detected clonal PCs in 19% and 23% of cases in which IHC or morphologic evaluation, respectively, failed to show a clonal plasma cell population. The MFC assay consistently detected clonal PC in bone marrow aspirates when serum M-protein levels were above 1g/dl. The frequency of clonal PC detection by MFC fell in concert with M-protein levels. However, in 11% of patients, MFC detected clonal PC after serum and urine immunofixation studies turned negative. Conclusion We conclude that the assay described herein is suitable when immunologic studies are indicated for either primary diagnosis or MRD detection in PC neoplasms. It equals or exceeds sensitivities reported in the literature and it is readily integrated into a high volume, multipurpose clinical flow cytometry laboratory. Disclosures: Keren: Sebia, Inc (Norcross, GA). : Consultancy.
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Agrawal, Amit, Ashish Shrivastava e Kartick C. Jana. "A Universal Input, Single-Stage AC–DC LED Driver for an Auditorium Light". Journal of Circuits, Systems and Computers 28, n.º 02 (12 de novembro de 2018): 1950024. http://dx.doi.org/10.1142/s0218126619500245.

Texto completo da fonte
Resumo:
Analysis, design and simulation of 126[Formula: see text]W power supply with better power quality are presented in the proposed work to run an auditorium light emitting diode (LED) light operating at universal AC input mains (90–270[Formula: see text]V). A single-ended primary inductance converter (SEPIC) topology is designed and driven in continuous conduction mode (CCM) with advance feedback system to maintain constant voltage at output. A proportional integral (PI) controller is also proposed to make the system stable, and stability analysis is discussed in detail with the help of transfer function derived from the state space model. Bode, Nyquist and Polar plots are clearly drawn using the MATLAB tool to claim the system stability. For justification of mathematical analysis, a simulation of the proposed LED driver is also performed in MATLAB–Simulink using sim-power toolbox. The simulation results show the improved value of power quality indices like power factor (PF), total harmonic distortion (THD) and crest factor (CF) with constant rating of 84[Formula: see text]V, 1.5[Formula: see text]A at output. Improved PF and reduced THD are under the limit of international standards like IEC-61000-3-2 Class C requirement.
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

WILLEY, VINCENT, JOHN B. BUSE, BRIAN HARTY, JULIE L. MITCHELL, BENJAMIN P. SOULE, HELENE N. CHRISTENSEN, MARK J. CZIRAKY e SIMON SKIBSTED. "752-P: Study Design and Baseline Profile for Patients with Type 2 Diabetes in the Semaglutide Once-Weekly Randomized Pragmatic Trial (SEPRA)". Diabetes 71, Supplement_1 (1 de junho de 2022). http://dx.doi.org/10.2337/db22-752-p.

Texto completo da fonte
Resumo:
SEPRA (NCT03596450) is a 2-yr, multicenter, open-label, randomized pragmatic clinical trial comparing the long-term effects of once-weekly subcutaneous semaglutide vs. standard of care (both added to ≤2 oral antidiabetic medications) in US health-insured adults with T2D and physician-determined inadequate glycemic control. SEPRA will assess glycemic control, weight loss, healthcare utilization, and patient-reported outcomes by collecting individual-level data from routine clinical practice and health insurance claims. The primary endpoint is the proportion of patients achieving HbA1c <7.0% at yr 1. The study design was evaluated using the Pragmatic Explanatory Continuum Indicator Summary (PRECIS) -2 assessment; it scored 4-5 in all 9 domains, suggesting a highly pragmatic study. Of 1,278 patients enrolled, 54% were male with mean (± SD) age 57.4 ± 11.1 yrs, BMI 35.7± 8.0 kg/m2, diabetes duration 7.4 ± 6.0 yrs, HbA1c 8.48 ± 1.6%, and mean individualized HbA1c target 6.66 ± 0.5%. Of note, 86.9% of patients had HbA1c >7.0% and most required sizeable reductions in HbA1c to reach the clinician-assigned individualized target. SEPRA will provide real-world evidence on the long-term effectiveness of semaglutide in a population with a broad range of HbA1c levels and other clinical characteristics when used as intensification early on in usual T2D care practice settings. Disclosure V.Willey: Employee; HealthCore Inc. J.B.Buse: Consultant; Alkahest, Anji, AstraZeneca, Boehringer Ingelheim International GmbH, Cirius Therapeutics, Inc., Eli Lilly and Company, Fortress biotech, GentiBio, Glycadia, Glyscend, Janssen Pharmaceuticals, Inc., Mellitus Health, Moderna, Inc., Pendulum Therapeutics, Praetego, LLC, Stability Health, Valo, Zealand Pharma A/S, Other Relationship; Adocia, AstraZeneca, Eli Lilly and Company, Intarcia Therapeutics, Inc., MannKind Corporation, Novo Nordisk, Sanofi, Senseonics, vTv Therapeutics, Research Support; AstraZeneca, Dexcom, Inc., Eli Lilly and Company, Novo Nordisk, vTv Therapeutics, Stock/Shareholder; Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio Pharmaceuticals, Inc., Praetego, LLC, Stability Health. B.Harty: None. J.L.Mitchell: None. B.P.Soule: Employee; Bristol-Myers Squibb Company, Novo Nordisk. H.N.Christensen: Employee; Novo Nordisk. M.J.Cziraky: None. S.Skibsted: Employee; Novo Nordisk. Funding Funded by Novo Nordisk Inc
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

BUSE, JOHN B., BENJAMIN P. SOULE, BRIAN J. HARTY, HELENE N. CHRISTENSEN, MARK J. CZIRAKY, VINCENT WILLEY e SIMON SKIBSTED. "776-P: Comparative Effectiveness of SC Semaglutide in Adults with T2D in U.S. Routine Clinical Practice—Year 1 Results of SEPRA, a Randomized Pragmatic Clinical Trial". Diabetes 72, Supplement_1 (20 de junho de 2023). http://dx.doi.org/10.2337/db23-776-p.

Texto completo da fonte
Resumo:
SEPRA, a 2-year, ongoing, open-label, randomized, pragmatic study (NCT03596450) compares the effects of once-weekly SC semaglutide (sema) with physician's choice SOC when added to ≤2 oral antidiabetic medications for treatment intensification in US health-insured adults with T2D. The objective is to generate real-world evidence to support routine clinical decision making and complement clinical trial data. The primary endpoint is the proportion of patients who achieve HbA1c <7% at 1 year. Patients (N=1278) were randomized to receive sema according to label (n=644) or SOC excluding sema (n=634). All other treatment was per routine clinical care. Baseline characteristics were comparable (Table 1). Most common SOC medications were other GLP-1RAs (71.3%) and SGLT2is (15.5%). Sema dosing at 1 year was 26.6% at 0.25 mg, 30.4% at 0.5 mg and 24.4% at 1 mg (10.6% ended study and 7.6% not on sema at year 1). Use of sema resulted in a significantly greater proportion of patients achieving HbA1c <7% and body weight reduction vs SOC at 1 year (Table 1). A lower proportion of sema patients required additional treatment intensification in year 1 of the study vs SOC. No new safety concerns were identified. SEPRA demonstrates the superior effect of sema vs physician's choice SOC and that sema is an efficacious, durable treatment option in routine clinical practice. Disclosure J.B.Buse: Consultant; Alkahest, Anji Pharmaceuticals, AstraZeneca, Bayer Inc., Biomea Fusion, Inc., Boehringer Ingelheim International GmbH, CeQur SA, Cirius Therapeutics, Inc., Corcept Therapeutics, Eli Lilly and Company, GentiBio, Glycadia, Glyscend Inc., Janssen Pharmaceuticals, Inc., Mellitus Health, Pendulum Therapeutics, Praetego, LLC, Stability Health, Terns, Inc, Valo, Other Relationship; Novo Nordisk, Research Support; Dexcom, Inc., Novo Nordisk, vTv Therapeutics, Stock/Shareholder; Glyscend Inc., Mellitus Health, Pendulum Therapeutics, PhaseBio Pharmaceuticals, Inc., Praetego, LLC, Stability Health. B.P.Soule: Employee; Novo Nordisk. B.J.Harty: Research Support; Novo Nordisk. H.N.Christensen: Employee; Novo Nordisk, Stock/Shareholder; Novo Nordisk A/S. M.J.Cziraky: Other Relationship; Novo Nordisk. V.Willey: Other Relationship; Novo Nordisk A/S. S.Skibsted: Employee; Novo Nordisk A/S. Funding Novo Nordisk
Estilos ABNT, Harvard, Vancouver, APA, etc.

Livros sobre o assunto "Sepia International Inc"

1

Lehmann, Matthias, e Christoph Kumpan, eds. European Financial Services Law. Nomos Verlagsgesellschaft mbH & Co. KG, 2019. http://dx.doi.org/10.5771/9783845279893.

Texto completo da fonte
Resumo:
This volume analyses and explains EU legislation governing financial services. It is for legal practitioners in international law firms, the financial industry, regulators, and academics needing an in-depth understanding of financial services regulations. It is intended to serve as a handy reference book, providing both easy-to-understand overviews of complex topics and insightful analyses of difficult legal issues. Experts renowned in their fields explain, article-by-article, the important EU directives and regulations governing financial services. Examples illustrate how important provisions apply in practice. Level ‡and ˆmeasures are put into context. The book is structured as follows: securities and markets Service market behaviour market transparency and information funds securities clearing and settlement payment services. For each subject area, the most relevant directives and regulations have been selected. Legal texts covered in this book include, among others, the following: MiFID II and MiFIR MAR and MAD Prospectus Directive PRIIP Regulation Transparency Directive Short Selling Regulation Rating Agency Regulation UCITS and AIFMD Venture Capital Funds Regulation Finality Directive Financial Collateral Directive EMIR SEPA Regulation.
Estilos ABNT, Harvard, Vancouver, APA, etc.

Capítulos de livros sobre o assunto "Sepia International Inc"

1

Scerri, Moira, e Renu Agarwal. "Service Enterprise Productivity in Action (SEPIA)". In International Series in Operations Research & Management Science, 93–114. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43437-6_6.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Smith, Stephanie J., e Rohini J. Manuel. "The Biology of Fungi". In Tutorial Topics in Infection for the Combined Infection Training Programme. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198801740.003.0009.

Texto completo da fonte
Resumo:
Fungi are found ubiquitously in the environment such as soil, water, and food. There are an estimated 1.5 million fungal species worldwide, although this number is felt to be grossly underestimated and is regularly updated. Of these vast numbers, around 500 fungi to date have been implicated in human disease. As opposed to bacteria, which are prokaryotes, fungi are eukaryotes, meaning they have a well-defined nucleus and have membrane- bound organelles in the cytoplasm, including an endoplasmic reticulum and a golgi apparatus. In 1969, the scientist R. H. Whittaker first proposed that organisms be classified into five kingdoms: Monera (Bacteria), Protista (Algae and Protozoans), Plantae (Plants), Mycetae (Fungi), and Animalia (Animals). Since then, there have been dramatic changes to the classifications of fungi, largely due to the appliance of phylogenetic molecular techniques. This has resulted in variances to the number of phylums, and the species assigned to them. Table 3.1 shows the seven phyla of the Fungi Kingdom. The majority of fungi pathogenic to humans inhabit the Ascomycota and Basidiomycota phyla. Fungi used to be dually named if they had a pleomorphic life cycle with sexual/ asexual stages (teleomorph/ anamorph, respectively), which meant that fungi often had two names and were classed differently. This practice was discontinued in January 2013 after the International Commission on the Taxonomy of Fungi decided that a ‘one fungus, one name’ approach should be followed. Fungi can be unicellular (yeast) or multicellular (fungi). Yeasts may look globose in nature when grown, whereas multicellular fungi grow as tubular, filamentous material called hyphae that can create a branching, hyphal network called a mycelium. Hyphae may have septa that cross their walls or be nonseptate, which is a method of differentiating fungi. An early hyphal outgrowth from a spore is called a germ tube. The germ tube test can be used to differentiate the yeasts Candida albicans and Candida dubliniensis from other Candida species. The fungal cell wall is composed of chitin and glucans, which are different components to the human cell wall. This means that they can be an effective target for antifungal therapy.
Estilos ABNT, Harvard, Vancouver, APA, etc.

Trabalhos de conferências sobre o assunto "Sepia International Inc"

1

ChandraSekar, T., A. Kannan, B. J. Rabi e V. Kumar. "Optimal utilization of pv power by controlling ti-sepic converter". In IET Chennai Fourth International Conference on Sustainable Energy and Intelligent Systems (SEISCON 2013). Institution of Engineering and Technology, 2013. http://dx.doi.org/10.1049/ic.2013.0301.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Gomathy AP, S., T. Raja, Akash kumar C, Abinaya Sri RS e Arjun M. "Design and Implementation of SEPIC Converter for Wind Energy System". In 2024 Second International Conference on Emerging Trends in Information Technology and Engineering (ICETITE). IEEE, 2024. http://dx.doi.org/10.1109/ic-etite58242.2024.10493802.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Mohanty, Gourab. "SEPIC Based Multi Input Dc-Dc Converter". In 2019 IEEE 5th International Conference for Convergence in Technology (I2CT). IEEE, 2019. http://dx.doi.org/10.1109/i2ct45611.2019.9033886.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Vinitha, s., e Jitha Varghese. "FLC Control Based Sepic for Power Factor Correction". In 2024 5th International Conference on Innovative Trends in Information Technology (ICITIIT). IEEE, 2024. http://dx.doi.org/10.1109/icitiit61487.2024.10579988.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Sreekala B. T. V. e Seema P. N. "Sepic PFC converter with notch filter based control". In 2015 International Conference on Technological Advancements in Power and Energy (TAP Energy). IEEE, 2015. http://dx.doi.org/10.1109/tapenergy.2015.7229624.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Kavitha Kumari, K. S., L. Chitra, J. Arun Kumar e S. C. Saranya. "ANN based SEPIC Converter for Electric Vehicle Charging". In 2023 Second International Conference on Advances in Computational Intelligence and Communication (ICACIC). IEEE, 2023. http://dx.doi.org/10.1109/icacic59454.2023.10435144.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Sangeetha, S., P. V. Ramakrishnan e P. R. Mini. "A Review on the Operation Strategies of Sepic Converter". In International Conference on Emerging Trends in Engineering & Technology (ICETET-2015). Singapore: Research Publishing Services, 2015. http://dx.doi.org/10.3850/978-981-09-5346-1_eee-546.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Balhan, B., R. A. Barlow, J. Borburgh e G. Raffaele. "Improvement of the CERN SPS electrostatic septa ion traps". In 2016 27th International Symposium on Discharges and Electrical Insulation in Vacuum (ISDEIV). IEEE, 2016. http://dx.doi.org/10.1109/deiv.2016.7764034.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Dimna Denny C e Shahin M. "Analysis of bidirectional SEPIC/Zeta converter with coupled inductor". In 2015 International Conference on Technological Advancements in Power and Energy (TAP Energy). IEEE, 2015. http://dx.doi.org/10.1109/tapenergy.2015.7229600.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Balhan, B., R. A. Barlow, J. Borburgh, A. Farricker, J. A. Mo e A. Prost. "Final Acceptance Testing of the CERN SPS Electrostatic Septa". In 2021 29th International Symposium on Discharges and Electrical Insulation in Vacuum (ISDEIV). IEEE, 2021. http://dx.doi.org/10.1109/isdeiv46977.2021.9587034.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!

Vá para a bibliografia